News

The House Energy and Commerce Subcommittee on Health Sept. 10 advanced the Title VIII Nursing Workforce Reauthorization Act (H.R. 3593), AHA-supported legislation that reauthorizes funding for Title VIII nursing workforce development programs. The bill will next be considered by the full committee.

The House Appropriations Committee Sept. 9 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services, Education, and related agencies by a 35-28 vote.

An AHA analysis released Sept. 10 highlights how tax-exempt hospitals provided nearly $150 billion in total benefits to their communities in 2022, the most recent year comprehensive data is available from the Internal Revenue Service.

The Centers for Medicare & Medicaid Services Sept. 9 issued preliminary guidance regarding the implementation of certain state-directed payment provisions in Section 71116 of the One Big Beautiful Bill Act.

The White House Sept. 9 released its “Make Our Children Healthy Again” strategy report, created to address childhood chronic diseases.

Health care leaders and other officials Sept.

A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer hospital stays than those under Traditional Medicare.

The AHA Sept. 9 announced Eric Fish, M.D., president and CEO of Schneck Medical Center in Seymour, Ind., has been elected to fill a vacancy on its Board of Trustees effective immediately for a term that ends Dec. 31, 2026.

Randy Fagin, M.D., chief quality officer at HCA Healthcare, shares how one of the nation’s largest health systems is putting artificial intelligence into practice by building responsible governance, reducing clinical and operational variance, and enhancing the work of front-line caregivers.

The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.

The Federal Trade Commission Sept. 5 voted 3-1 to vacate the noncompete final rule issued last year by the previous administration. The rule banned, as an unfair method of competition, contractual terms prohibiting workers from pursuing certain employment after their contract with an employer ends

The White House Sept. 5 issued an executive order modifying the scope of reciprocal tariffs announced in April to establish a framework of trade deals with international partners on certain goods such as critical minerals and pharmaceutical products.

A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with quality measures.

The Federal Trade Commission Sept. 4 released a request for information on noncompete agreements. The agency said it seeks to “better understand the scope, prevalence, and effects of employer noncompete agreements, as well as to gather information to inform possible future enforcement actions.

The AHA and other national hospital organizations Sept. 5 urged Senate and House leadership to act on preventing Medicaid Disproportionate Share Hospital reductions from taking effect Oct. 1.

Congress returns to Washington, D.C., this week facing a long list of things to do,

The Department of Health and Human Services Sept. 4 announced new hardship exemption guidance that would allow consumers ineligible for premium tax credits or cost-sharing reductions to enroll in catastrophic health coverage.

The AHA Sept. 4 expressed support for the Hospitals As Naloxone Distribution Sites Act (H.R. 5120), legislation that would require Medicare and Medicaid to cover costs when hospitals provide naloxone to patients at risk of an overdose at no cost to patients.

The Cybersecurity and Infrastructure Security Agency, National Security Agency and international agencies Sept. 3 released joint guidance outlining a “software bill of materials” for organizations to strengthen cybersecurity, reduce risk and decrease costs.

The Food and Drug Administration has identified Class I recalls for the following products due to the potential for serious injury or death: